Allopurinol as Prophylaxis Against Pouchitis Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis: A Randomized Placebo-controlled Double-blind Study
| Autor: | I Magnusson, Y Raab, T. Öresland, M Joelsson, T Bark, T Hallgren, H Jiborn, Rune Sjödahl, Björn Öjerskog, K Gullberg, Magnus Andersson |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male musculoskeletal diseases congenital hereditary and neonatal diseases and abnormalities medicine.medical_specialty Randomization Adolescent Allopurinol medicine.medical_treatment Anal Canal Rectum Pouchitis Anastomosis Placebo digestive system Gastroenterology Postoperative Complications Double-Blind Method Internal medicine medicine Humans Aged business.industry Proctocolectomy Anastomosis Surgical Proctocolectomy Restorative digestive oral and skin physiology nutritional and metabolic diseases Middle Aged medicine.disease Ulcerative colitis Surgery medicine.anatomical_structure Colitis Ulcerative Female business medicine.drug |
| Zdroj: | Scandinavian Journal of Gastroenterology. 36:1179-1184 |
| ISSN: | 1502-7708 0036-5521 |
| DOI: | 10.1080/00365520152584815 |
| Popis: | Pouchitis is the major long-term complication of restorative proctocolectomy for ulcerative colitis (UC). Allopurinol is a scavenger of oxygen-derived free radicals, which it is suggested play a role in the development of UC and pouchitis. The first aim was to test the hypothesis that the incidence of pouchitis can be reduced by prophylactic Allopurinol, and secondly to evaluate if Allopurinol influences the overall pouch function.273 patients with UC who were planned for proctocolectomy and ileal pouch-anal anastomosis at 12 centres in Sweden between October 1994 and June 1997 were offered the opportunity to participate. 184 patients (67%) were randomized to receive postoperative prophylactic Allopurinol 100 mg twice daily or placebo. All 273 patients had clinical and endoscopic follow-up at 1, 3, 6, 12, 18, 24 months after surgery.Of the 184 randomized patients, 94 were randomized to Allopurinol and 90 to placebo; 116 patients (63%) completed follow-up and the crude incidence of pouchitis among those patients fullfilling the protocol was 31% in the Allopurinol group and 28% in the placebo group (ns). The cumulative risk for a first attack of pouchitis was 30% and 26% after 24 months (ns). The overall pouch function improved over time and did not differ significantly between the two groups.Prophylactic Allopurinol did not reduce the risk of a first attack of pouchitis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|